Finepoint Capital’s Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 CLDI.WS Stock Holding History

Finepoint Capital’s Portfolio CLDI.WS Stock Details CLDI.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-655,200	Closed	-$8.58K	–	31
2024 Q3	$8.58K	Hold	655,200	–	–	﹤0.01%	26
2024 Q2	$27.6K	Hold	655,200	–	–	0.01%	22
2024 Q1	$34.1K	Hold	655,200	–	–	0.01%	23
2023 Q4	$32.8K	Hold	655,200	–	–	0.01%	22
2023 Q3	$144K	Hold	655,200	–	–	0.07%	21
2023 Q2	$85.2K	Hold	655,200	–	–	0.03%	25
2023 Q1	$26.9K	Hold	655,200	–	–	0.01%	36
2022 Q4	$33K	Hold	655,200	–	–	0.01%	33
2022 Q3	$37K	Hold	655,200	–	–	0.01%	39
2022 Q2	$59K	Hold	655,200	–	–	0.02%	50
2022 Q1	$236K	Hold	655,200	–	–	0.08%	39
2021 Q4	$328K	Buy	+655,200	New	+$370K	0.08%	56

Other funds holding CLDI.WS

EAM

Exos Asset Management New York $2.32K AUM 108.13% 1-Year Est. Return

Finepoint Capital's CLDI.WS Position: Q4 2024 in Review

Finepoint Capital sold out of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) in Q4 2024, closing a stake of 655,200 shares — an estimated $8.58K sold.

Finepoint Capital first reported a position in CLDI.WS in Q4 2021 and held it in 12 quarters. The position peaked at $328K in Q4 2021. 1 fund tracked by Wall St. Rank holds CLDI.WS as of Q4 2024.

Finepoint Capital reported no remaining Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position as of Q4 2024 after selling out during the quarter.
Finepoint Capital sold 655,200 Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 shares in Q4 2024, an estimated $8.58K.
Finepoint Capital first reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in Q4 2021 and held it in 12 quarters.
Finepoint Capital's Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 position peaked at $328K in Q4 2021.
1 fund tracked by Wall St. Rank held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 as of Q4 2024.

Based on Finepoint Capital's 13F filing for Q4 2024, filed 13 Feb 2025.